ZFPL1 and colorectal carcinoma: Furthermore, Sal B synergized effectively with anti‐PD‐1 immunotherapy in vivo, highlighting the therapeutic potential of targeting the ZFPL1‐ASS1 pathway in combination with immune checkpoint blockade for advanced CRC.